NASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis $65.30 +0.13 (+0.20%) (As of 04:02 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Incyte Stock (NASDAQ:INCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$65.08▼$65.9150-Day Range$61.26▼$68.0652-Week Range$50.27▼$70.36Volume609,443 shsAverage Volume2.33 million shsMarket Capitalization$14.66 billionP/E Ratio181.39Dividend YieldN/APrice Target$73.42Consensus RatingHold Company OverviewIncyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Read More… The gold trades I'm making right now (Ad)Back in November, gold made a tiny move of 1.6%. But using a special type of gold trade, I saw a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there were smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period.It's all about catching what I call "Acceleration Cycles." Incyte Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks94th Percentile Overall ScoreINCY MarketRank™: Incyte scored higher than 94% of companies evaluated by MarketBeat, and ranked 77th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 8 buy ratings, 12 hold ratings, and 1 sell rating.Amount of Analyst CoverageIncyte has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth674.24% Earnings GrowthEarnings for Incyte are expected to grow by 674.24% in the coming year, from $0.66 to $5.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 181.42, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 129.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 181.42, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 134.45.Price to Earnings Growth RatioIncyte has a PEG Ratio of 5.30. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 2.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Incyte's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.57% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Incyte has recently decreased by 29.46%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.63 Percentage of Shares Shorted3.57% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Incyte has recently decreased by 29.46%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.46 News SentimentIncyte has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Incyte this week, compared to 9 articles on an average week.Search InterestOnly 3 people have searched for INCY on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows6 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,652,914.00 in company stock.Percentage Held by Insiders17.50% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. INCY Stock News HeadlinesIncyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers ListOctober 24 at 2:03 PM | businesswire.comDermatologist Sandra Lee’s Tips for Treating Eczema at HomeOctober 23 at 8:31 PM | msn.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Incyte (INCY) Gets a Buy from TD CowenOctober 22 at 11:48 PM | markets.businessinsider.comState Street Corp's Strategic Reduction in Incyte Corp HoldingsOctober 18, 2024 | finance.yahoo.comIncyte Announces Health Canada Approval of OPZELURA® (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD) and Nonsegmental VitiligoOctober 16, 2024 | finance.yahoo.comWhat to Expect From Incyte's Next Quarterly Earnings ReportOctober 16, 2024 | msn.comAlpha-9 Oncology Appoints Jean-Jacques Bienaimé and Dr. Steven Stein to its Board of DirectorsOctober 15, 2024 | finance.yahoo.comSee More Headlines INCY Stock Analysis - Frequently Asked Questions How have INCY shares performed this year? Incyte's stock was trading at $62.79 at the beginning of the year. Since then, INCY stock has increased by 4.0% and is now trading at $65.31. View the best growth stocks for 2024 here. How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) posted its quarterly earnings data on Tuesday, July, 30th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.78 by $2.60. The company's revenue for the quarter was up 9.3% on a year-over-year basis. Read the conference call transcript. Who are Incyte's major shareholders? Incyte's top institutional investors include Allspring Global Investments Holdings LLC (0.22%), Grimes & Company Inc. (0.08%), Shikiar Asset Management Inc. (0.07%) and DekaBank Deutsche Girozentrale (0.07%). Insiders that own company stock include Steven H Stein, Maria E Pasquale, Barry P Flannelly, Vijay K Iyengar, Jonathan Elliott Dickinson, Thomas Tray, Bros Advisors Lp Baker, Wendy L Dixon and Paula J Swain. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings7/30/2024Today10/24/2024Next Earnings (Confirmed)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CUSIP45337C10 CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,524Year Founded1991Price Target and Rating Average Stock Price Target$73.42 High Stock Price Target$93.00 Low Stock Price Target$48.00 Potential Upside/Downside+12.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$3.30 Trailing P/E Ratio181.03 Forward P/E Ratio98.74 P/E Growth5.3Net Income$597.60 million Net Margins2.52% Pretax Margin9.10% Return on Equity0.75% Return on Assets0.56% Debt Debt-to-Equity Ratio0.01 Current Ratio1.92 Quick Ratio1.84 Sales & Book Value Annual Sales$3.86 billion Price / Sales3.79 Cash Flow$2.41 per share Price / Cash Flow27.01 Book Value$23.16 per share Price / Book2.81Miscellaneous Outstanding Shares224,541,000Free Float158,701,000Market Cap$14.63 billion OptionableOptionable Beta0.73 Social Links This page (NASDAQ:INCY) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredAre You Holding the Winning Hand in the Copper Market?Are You Holding the Winning Hand in the Copper Market?Market JAR | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAccording to Steven Lubka, head of a private equity firm with over $250M in assets under management, "Bitcoin ...Crypto 101 Media | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.